Companies /Healthcare

Doximity Inc - Class A

NYSE: DOCS Health Information Services
$26.32
▼ $0.03 (−0.11%) today
Markets closed · 6:00am ET

Q1 2027 Earnings

Reported Aug 6, 2026, 4:04pm ET · SEC source
$0.29
Miss −4.20%
EPS · est. $0.30 Adjusted
$156.6M
Beat +3.22%
Revenue · est. $151.7M
2 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
0+60%+120%+180%Aug 6Aug 7report 4:04pm ETearnings+0.6%+35.4%
0+60%+120%+180%Aug 6Aug 7earnings+0.6%+35.4%
DOCS +35.4%S&P 500 +0.6%
0+60%+120%+180%Aug 6Aug 7report 4:04pm ETearnings+1.1%+35.4%
0+60%+120%+180%Aug 6Aug 7earnings+1.1%+35.4%
DOCS +35.4%NASDAQ +1.1%
−40%−20%0+20%Aug 5Aug 14report 4:04pm ETearnings+1.0%−28.9%
−40%−20%0+20%Aug 5Aug 14earnings+1.0%−28.9%
DOCS −28.9%S&P 500 +1.0%
−40%−20%0+20%Aug 5Aug 14report 4:04pm ETearnings+2.3%−28.9%
−40%−20%0+20%Aug 5Aug 14earnings+2.3%−28.9%
DOCS −28.9%NASDAQ +2.3%
+32.62%
Day of report
−6.46%
Next session
−9.49%
One week

Did DOCS Beat Earnings? Q1 2027 Results

Doximity delivered a mixed fiscal first quarter for 2027, topping revenue expectations while falling short on profitability, a combination that sent shares lower amid broader concerns about demand trends. The medical networking platform posted revenue of $156.62 million, up 7.3% year-over-year and ahead of the $151.73 million consensus estimate, but adjusted non-GAAP diluted EPS of $0.29 missed the $0.30 analyst estimate by 4.20%. The earnings shortfall traced largely to surging costs, with stock-based compensation jumping roughly 68% to $36.75 million and research and development spending climbing to $38.48 million from $26.80 million a year ago, compressing GAAP net income margin from 36.5% to 15.5%. Adjusted EBITDA margin also contracted to 47.7% from 54.7%. Investors parsed the results with some caution, as softer billings raised questions about pharma marketing demand. Still, management pointed to strong AI product engagement and issued Q2 revenue guidance of $170 million to $171 million, while raising full-year revenue guidance to a range of $671 million to $681 million, signaling confidence in an acceleration ahead.

Key Takeaways
  • 7% year-over-year revenue growth driven by accelerated subscription revenue
  • Workflow active prescriber growth of more than 30% year-over-year
  • Record engagement on the platform
  • AI Search query growth of over 25% quarter-over-quarter

“We're proud that our clinical AI assistant, Doximity Ask, was the top-performing U.S.-based model in the NOHARM benchmark while we delivered another quarter of record engagement.”

Doximity CEO, on the earnings call

Forward Guidance & Outlook

For fiscal Q2 2027 (ending September 30, 2026), Doximity guides revenue of $170 million to $171 million and adjusted EBITDA of $80.5 million to $81.5 million. For the full fiscal year ending March 31, 2027, the company updated guidance to revenue of $671 million to $681 million and adjusted EBITDA of $309 million to $329 million.

DOCS YoY Financials

Q1 2027 vs Q1 2026 · SEC filings Q1 2026 Q1 2027
$0$50.0M$100.0M$150.0M$145.9M$156.6MRevenue$130.1M$132.9MGross Profit$54.5M$33.6MOperating Income$53.3M$24.3MNet Income
$0$50.0M$100.0M$150.0MRevenueGross ProfitOperating IncomeNet Income

DOCS Revenue by Segment

Subscription Revenue

Figures from SEC filings and company reports. Not investment advice.